Please ensure Javascript is enabled for purposes of website accessibility

Why Cellect Biotechnology Stock Is Skyrocketing Today

By George Budwell - Updated Mar 27, 2017 at 2:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stem-cell specialist's first successful transplant caused its shares to explode higher on Monday.

What happened

Cellect Biotechnology (APOP), an Israeli-based stem-cell company, today announced the first successful stem cell transplant procedure using its ApoGraft technology in a combined phase 1/2 clinical trial in a blood cancer patient, causing its shares to rise by as much as 115%. The company's stock has since cooled off, but is still up by 80% as of 3:00 p.m. EDT.   

Rocket blasting off into the atmosphere

Image source: Getty Images.

So what

Even though stem cell transplants can be a curative treatment for many blood disorders and blood-related cancers, they tend to be a treatment of last resort because of their life-threatening side effects, such as graft-versus-host disease (GvHD). So, if Cellect's ApoGraft technology turns out to be a viable workaround, it would be a major advancement in the field, and potentially an extremely lucrative product for the company. 

Now what

While Cellect's announcement is indeed exciting, its stock still isn't a great long-term bet. Cellect exited 2016 with a paltry $8 million in cash and ApoGraft is probably five to six years away from reaching the market. This current trial, after all, is simply a safety and proof-of-concept study that's not designed to provide a basis for a regulatory approval.

In addition, Bellicum Pharmaceuticals' adjunct T-cell therapy BPX-501 could reach the European market as one possible solution to the GvHD problem in blood cancer patients by early 2019, and in the U.S. by perhaps 2020. In other words, Bellicum has a significant head start on Cellect, which may diminish the commercial prospects of ApoGraft moving forward.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cellect Biotechnology Ltd. Stock Quote
Cellect Biotechnology Ltd.
APOP

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.